Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ERSP deflates Leading Edge's enhancement claims

This article was originally published in The Tan Sheet

Executive Summary

The Electronic Retailing Self-Regulation Program recommends Leading Edge Marketing modify or discontinue some efficacy claims for its male enhancement products. ERSP in a Sept. 15 report also recommends Leading Edge disclose more clearly on its website the relationship between the products, reviewers and the firm. Following an anonymous challenge, ERSP recommends the company modify claims related to stamina, erection size and "more powerful orgasm" for its products VigRX, VigRX Plus and VigRX Oil. No human studies were conducted with the products, and Leading Edge's data did not adequately support the claims, says the Council of Better Business Bureaus division. ERSP notes the Earth City, Mo.-based firm modified its website, but did not adequately disclose that it owns, which purports to be independent. ERSP notes three Leading Edge-affiliated websites with customer testimonials do not comply with 2009 Federal Trade Commission guideline requirement to disclose typical results from use of the product (1"The Tan Sheet" Oct. 12, 2009). The company said it plans to comply

You may also be interested in...

FTC Testimonial Guide Moves Past "Results Not Typical," Enters Blog Era

The Federal Trade Commission raised the bar on substantiation and disclosure of "typical results" in testimonials and endorsements in advertising, in a revised guide released Oct. 5

Huma Secures EU MDR Approval For Medtech Software That Can Be Used In Any Disease

Huma Therapeutics has secured the first ever EU regulatory approval for a “disease agnostic” class IIb medtech software platform. CEO Dan Vahdat tells Medtech Insight how the product can be configured to monitor patients with any condition.

Moderna CEO Hearing Highlights Dissatisfaction With Patient Assistance Programs

There was bipartisan agreement that Moderna need to ensure that its patient assistance program will be easily accessible for under- and uninsured patients once the US switches to a commercial market for COVID vaccines – a sign of broader frustration with industry copay support initiatives.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts